Stock Pick

Healthcare shares lead the ASX 200 again as sector rotation gathers pace

Written by

openjargon

in

A man wearing a white coat holds his hands up and mouth open with joy.

ASX 200 healthcare shares led the 11 market sectors last week with a 5.64% gain over the five trading days.

The S&P/ASX 200 Index (ASX: XJO) lifted 0.92% in the final trading week of FY26. 

The ASX 200 finished the week at 8,844.4 points.

This is the second time in three weeks that ASX 200 healthcare shares have been out in front. 

A sector rotation appears underway as value investors swoop on blue-chip favourites like CSL Ltd (ASX: CSL) and Pro Medicus Ltd (ASX: PME). 

The healthcare sector appears to have turned on 3 June when the S&P/ASX 200 Health Care Index (ASX: XHJ) hit a 9-year low.

That represented a 39% decline over 12 months. You can read comprehensive analysis of why the healthcare sector struggled in FY26 here.

Since then, healthcare shares have increased 20% in just one month compared to an 0.7% rise for the ASX 200 overall. 

In a new note, top broker UBS said ASX 200 healthcare shares and US biotech stocks both rose strongly in June, commenting:

There was limited company specific news to explain this recovery, suggesting it was due to broader market forces including sector rotation.

Healthcare was the worst performer among the 11 market sectors in FY26. You can read more about the market’s winners and losers in FY26 here. 

Now, let’s review some individual stock performances from last week.

Healthcare shares led the ASX sectors last week

The CSL share price rose 6.05% to $121.81 last week, and it’s up 32% since 3 June. 

Pro Medicus shares jumped 11% to $209.65 on Friday, and are up 31% since 3 June. 

Resmed CDI (ASX: RMD) shares ascended 5.39% to $30.50 last week, and are 18% higher since 3 June. 

Sonic Healthcare Ltd (ASX: SHL) shares rose 4.06% to $21.25 last week, and are up 13.1% over the month. 

The Ramsay Health Care Ltd (ASX: RHC) share price lifted 2.46% to $44.16 last week, and is up 21% since 3 June. 

The Cochlear Ltd (ASX: COH) share price increased 5.87% to $124.96 last week, and is up 31% since 3 June. 

Telix Pharmaceuticals Ltd (ASX: TLX) shares ripped 10.11% to $16.88 on Friday, and are up 38% over the month.

Respiratory imaging technology company 4DMedical Ltd (ASX: 4DX) rose 2.16% to $4.25 per share on Friday. 

4DMedical shares are up 12% since 3 June. 

The ASX 200 healthcare share was the best performer of the entire ASX 200 in FY26 after skyrocketing 1,786%. 

ASX 200 market sector snapshot

Here’s how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

S&P/ASX 200 market sector Change last week
Healthcare (ASX: XHJ) 5.64%
Information Technology (ASX: XIJ) 2.42%
Materials (ASX: XMJ) 2.08%
Financials (ASX: XFJ) 1.74%
Energy (ASX: XEJ) 0.74%
Communication (ASX: XTJ) (0.91%)
Industrials (ASX: XNJ) (1.04%)
Consumer Discretionary (ASX: XDJ) (1.31%)
Consumer Staples (ASX: XSJ) (1.68%)
A-REIT (ASX: XPJ) (3.7%)
Utilities (ASX: XUJ) (5.78%)

 

The post Healthcare shares lead the ASX 200 again as sector rotation gathers pace appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 16 June 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Cochlear, Pro Medicus, Sonic Healthcare, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts